Skip to main content

HBV

5
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Kite Pharma
Kite PharmaCA - El Segundo
2 programs
2
TAFPhase 31 trial
TAFPhase 31 trial
Active Trials
NCT02836249Completed181Est. Aug 2023
NCT02836236Completed155Est. Sep 2023
Golden Biotechnology
Golden BiotechnologyTaiwan - Taipei
1 program
1
AntroquinonolPhase 21 trial
Active Trials
NCT03625102Completed60Est. Jun 2023
F-star Therapeutics
F-star TherapeuticsUK - Cambridge
1 program
1
inarigivir soproxilPhase 2
Star Therapeutics
Star TherapeuticsCA - South SF
1 program
1
inarigivir soproxilPhase 21 trial
Active Trials
NCT03932513Terminated8Est. Dec 2019
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
nucleoside analogues or interferonN/A1 trial
Active Trials
NCT05965388Not Yet Recruiting5,000Est. Feb 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Kite PharmaTAF
Kite PharmaTAF
Star Therapeuticsinarigivir soproxil
Golden BiotechnologyAntroquinonol
UNION therapeuticsnucleoside analogues or interferon

Clinical Trials (5)

Total enrollment: 5,404 patients across 5 trials

NCT02836249Kite PharmaTAF

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)

Start: Jun 2015Est. completion: Aug 2023181 patients
Phase 3Completed
NCT02836236Kite PharmaTAF

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)

Start: Jun 2015Est. completion: Sep 2023155 patients
Phase 3Completed
NCT03932513Star Therapeuticsinarigivir soproxil

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

Start: Apr 2019Est. completion: Dec 20198 patients
Phase 2Terminated
NCT03625102Golden BiotechnologyAntroquinonol

A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B

Start: Aug 2018Est. completion: Jun 202360 patients
Phase 2Completed
NCT05965388UNION therapeuticsnucleoside analogues or interferon

Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy

Start: Dec 2023Est. completion: Feb 20295,000 patients
N/ANot Yet Recruiting

Related Jobs

Associate Director, Analytics & Forecasting – Hepatitis B Vaccines

SanofiSanofi
Morristown, NJ
6d ago

Senior Therapeutic Specialist - Hepatitis B/D Hartford, CT

Gilead SciencesGilead Sciences
United States - Field; United States - Connecticut - Hartford; United States - Connecticut - Stamford (Field-Based)
2mo ago
$133K - $172K/yr

Therapeutic Specialist - Hepatitis B/D - Minneapolis, MN

Gilead SciencesGilead Sciences
United States - Field
3mo ago
$115K - $149K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

HBV | Pipeline & Competitive Landscape | Formulate